Abstract
Summary
The Europe sarcopenia treatment market is expected to reach USD 1,033,968.39 thousand by 2030 from USD 725,593.95 thousand in 2022, growing at a CAGR of 4.6% in the forecast period of 2023 to 2030
Market Segmentation
Europe Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, And Rest Of Europe) - Industry Trends and Forecast to 2030
Overview of Europe Sarcopenia Treatment Market Dynamics:
Driver
• Rising prevalence of sarcopenia
Restraint
• Lack of standardized diagnosis
Opportunity
• Strategic initiatives by key market players
Market Players
Some of the key market players operating in the Europe sarcopenia treatment market are listed below:
• Abbott,
• Nestlé Health Science (A subsidiary of Nestlé S.A.)
• Novartis AG
• Sanofi
• Haleon Group of Companies
• BASF SE
• DSM
• Fermenta Biotech Limited
• AstaReal Co., Ltd.
• Metagenics
• Wellona Pharma
• The Vitamin Company India
• Healing Pharma India Pvt. Ltd
• Others
Table of Contents
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF THE EUROPE SARCOPENIA TREATMENT MARKET 26
1.4 CURRENCY AND PRICING 28
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 DBMR TRIPOD DATA VALIDATION MODEL 34
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.6 MULTIVARIATE MODELLING 38
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 38
2.8 MARKET END USER COVERAGE GRID 39
2.9 DBMR MARKET POSITION GRID 40
2.10 VENDOR SHARE ANALYSIS 42
2.11 SECONDARY SOURCES 43
2.12 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
4.1 PESTEL ANALYSIS 48
4.2 PORTER’S FIVE FORCES MODEL 49
4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 50
5 EUROPE SARCOPENIA TREATMENT MARKET: REGULATIONS 51
5.1 REGULATIONS IN U.S 51
5.2 REGULATIONS IN EUROPE 51
5.3 REGULATIONS IN AUSTRALIA 52
5.4 REGULATIONS IN SOUTH AFRICA 52
6 MARKET OVERVIEW 53
6.1 DRIVERS 55
6.1.1 RISING PREVALENCE OF SARCOPENIA 55
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 55
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 56
6.2 RESTRAINTS 57
6.2.1 LACK OF STANDARDIZED DIAGNOSIS 57
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 57
6.3 OPPORTUNITIES 58
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 58
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 58
6.4 CHALLENGES 59
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 59
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 60
7 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 61
7.1 OVERVIEW 62
7.2 VITAMIN/DIETARY SUPPLEMENTS 65
7.2.1 VITAMIN SUPPLEMENTS 66
7.2.2 PROTEIN SUPPLEMENTS 66
7.2.3 FATTY ACID SUPPLEMENTS 66
7.2.4 CREATINE 66
7.2.5 WHEY PROTEINS 66
7.2.6 L-CARNITINE 66
7.2.7 SOY 66
7.2.8 BETA-ALANINE 66
7.2.9 OSTARINE 66
7.2.10 COLLAGEN PEPTIDES 66
7.2.11 LIGANDROL 67
7.2.12 BRANCH-CHAIN AMINO ACIDS 67
7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 67
7.2.14 MEDIUM CHAIN TRIGLYCERIDES 67
7.2.15 OTHERS 67
7.3 MEDICATIONS 67
7.3.1 OFF LABEL DRUGS 68
7.3.2 EMERGING DRUGS 68
- 7.3.2.1 ACE INHIBITORS 68
- 7.3.2.2 APPETITE STIMULANTS 68
- 7.3.2.3 ORAL ANTIDIABETIC DRUGS 68
- 7.3.2.4 OTHERS 69
7.4 OTHERS 69
8 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE 70
8.1 OVERVIEW 71
8.2 PRIMARY SARCOPENIA 74
8.2.1 VITAMIN/DIETARY SUPPLEMENTS 74
8.2.2 MEDICATIONS 74
8.2.3 OTHERS 74
8.3 SECONDARY SARCOPENIA 75
8.3.1 VITAMIN/DIETARY SUPPLEMENTS 75
8.3.2 MEDICATIONS 75
8.3.3 OTHERS 75
9 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES 76
9.1 OVERVIEW 77
9.2 PRE-SARCOPENIA 80
9.3 SARCOPENIA 80
9.4 SEVERE SARCOPENIA 81
10 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 82
10.1 OVERVIEW 83
10.2 ORAL 86
10.3 INJECTABLES 86
10.4 OTHERS 87
11 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER 88
11.1 OVERVIEW 89
11.2 MALE 92
11.3 FEMALE 92
12 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER 93
12.1 OVERVIEW 94
12.2 HOSPITALS 97
12.2.1 PUBLIC 97
12.2.2 PRIVATE 97
12.3 SPECIALTY CLINICS 98
12.4 HOME HEALTHCARE 98
12.5 OTHERS 99
13 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 100
13.1 OVERVIEW 101
13.2 DIRECT TENDER 104
13.3 RETAIL SALES 104
13.3.1 HOSPITAL PHARMACIES 105
13.3.2 ONLINE PHARMACIES 105
13.3.3 OTHERS 105
13.4 OTHERS 105
14 EUROPE SARCOPENIA TREATMENT MARKET, BY REGION 106
14.1 EUROPE 109
14.1.1 GERMANY 116
14.1.2 FRANCE 122
14.1.3 U.K 128
14.1.4 ITALY 134
14.1.5 SPAIN 140
14.1.6 RUSSIA 146
14.1.7 TURKEY 152
14.1.8 BELGIUM 158
14.1.9 NETHERLANDS 164
14.1.10 SWITZERLAND 170
14.1.11 DENMARK 176
14.1.12 NORWAY 182
14.1.13 SWEDEN 188
14.1.14 POLAND 194
14.1.15 FINLAND 201
14.1.16 REST OF EUROPE 207
15 EUROPE SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 208
15.1 COMPANY SHARE ANALYSIS: EUROPE 208
16 SWOT ANALYSIS 209
17 COMPANY PROFILE 210
17.1 ABBOTT 210
17.1.1 COMPANY SNAPSHOT 210
17.1.2 REVENUE ANALYSIS 210
17.1.3 COMPANY SHARE ANALYSIS 211
17.1.4 PRODUCT PORTFOLIO 211
17.1.5 RECENT DEVELOPMENT 211
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.) 212
17.2.1 COMPANY SNAPSHOT 212
17.2.2 REVENUE ANALYSIS 212
17.2.3 COMPANY SHARE ANALYSIS 213
17.2.4 PRODUCT PORTFOLIO 213
17.2.5 RECENT DEVELOPMENT 213
17.3 NOVARTIS AG 214
17.3.1 COMPANY SNAPSHOT 214
17.3.2 REVENUE ANALYSIS 214
17.3.3 COMPANY SHARE ANALYSIS 215
17.3.4 PRODUCT PORTFOLIO 215
17.3.5 PIPELINE PORTFOLIO 215
17.3.6 RECENT DEVELOPMENT 215
17.4 SANOFI 216
17.4.1 COMPANY SNAPSHOT 216
17.4.2 REVENUE ANALYSIS 216
17.4.3 COMPANY SHARE ANALYSIS 217
17.4.4 PRODUCT PORTFOLIO 217
17.4.5 RECENT DEVELOPMENT 217
17.5 HALEON GROUP OF COMPANIES 218
17.5.1 COMPANY SNAPSHOT 218
17.5.2 REVENUE ANALYSIS 218
17.5.3 COMPANY SHARE ANALYSIS 219
17.5.4 PRODUCT PORTFOLIO 219
17.5.5 RECENT DEVELOPMENT 219
17.6 ASTAREAL CO., LTD 220
17.6.1 COMPANY SNAPSHOT 220
17.6.2 PRODUCT PORTFOLIO 220
17.6.3 RECENT DEVELOPMENT 220
17.7 BASF SE 221
17.7.1 COMPANY SNAPSHOT 221
17.7.2 REVENUE ANALYSIS 221
17.7.3 PRODUCT PORTFOLIO 222
17.7.4 RECENT DEVELOPMENT 222
17.8 BIOGEN SA 223
17.8.1 COMPANY SNAPSHOT 223
17.8.2 PRODUCT PORTFOLIO 223
17.8.3 RECENT DEVELOPMENT 223
17.9 BIOTHRIVE SCIENCES 224
17.9.1 COMPANY SNAPSHOT 224
17.9.2 PRODUCT PORTFOLIO 224
17.9.3 RECENT DEVELOPMENT 224
17.10 DSM 225
17.10.1 COMPANY SNAPSHOT 225
17.10.2 REVENUE ANALYSIS 225
17.10.3 PRODUCT PORTFOLIO 226
17.10.4 RECENT DEVELOPMENT 226
17.11 FERMENTA BIOTECH LIMITED 227
17.11.1 COMPANY SNAPSHOT 227
17.11.2 REVENUE ANALYSIS 227
17.11.3 PRODUCT PORTFOLIO 228
17.11.4 RECENT DEVELOPMENT 228
17.12 HEALING PHARMA INDIA PVT. LTD 229
17.12.1 COMPANY SNAPSHOT 229
17.12.2 PRODUCT PORTFOLIO 229
17.12.3 RECENT DEVELOPMENT 229
17.13 METAGENICS 230
17.13.1 COMPANY SNAPSHOT 230
17.13.2 PRODUCT PORTFOLIO 230
17.13.3 RECENT DEVELOPMENT 230
17.14 THE VITAMIN COMPANY INDIA 231
17.14.1 COMPANY SNAPSHOT 231
17.14.2 PRODUCT PORTFOLIO 231
17.14.3 RECENT DEVELOPMENT 231
17.15 WELLONA PHARMA 232
17.15.1 COMPANY SNAPSHOT 232
17.15.2 PRODUCT PORTFOLIO 232
17.15.3 RECENT DEVELOPMENT 232
17.16 ARMGO PHARMA, INC 233
17.16.1 COMPANY SNAPSHOT 233
17.16.2 PIPELINE PORTFOLIO 233
17.16.3 RECENT DEVELOPMENT 233
17.17 BIOPHYTIS 234
17.17.1 COMPANY SNAPSHOT 234
17.17.2 PIPELINE PORTFOLIO 234
17.17.3 RECENT DEVELOPMENT 234
17.18 DYSTROGEN THERAPEUTICS CORP 235
17.18.1 COMPANY SNAPSHOT 235
17.18.2 PIPELINE PORTFOLIO 235
17.18.3 RECENT DEVELOPMENT 235
17.19 IMMUNOFORGE INC 236
17.19.1 COMPANY SNAPSHOT 236
17.19.2 PIPELINE PORTFOLIO 236
17.19.3 RECENT DEVELOPMENT 236
17.20 MYMD PHARMACEUTICALS 237
17.20.1 COMPANY SNAPSHOT 237
17.20.2 PIPELINE PORTFOLIO 237
17.20.3 RECENT DEVELOPMENT 237
17.21 NMD PHARMA A/S 238
17.21.1 COMPANY SNAPSHOT 238
17.21.2 PIPELINE PORTFOLIO 238
17.21.3 RECENT DEVELOPMENT 238
17.22 ONCOCROSS CO., LTD 239
17.22.1 COMPANY SNAPSHOT 239
17.22.2 PIPELINE PORTFOLIO 239
17.22.3 RECENT DEVELOPMENT 239
17.23 OPKO HEALTH, INC 240
17.23.1 COMPANY SNAPSHOT 240
17.23.2 REVENUE ANALYSIS 240
17.23.3 PIPELINE PORTFOLIO 241
17.23.4 RECENT DEVELOPMENT 241
17.24 REGENERON PHARMACEUTICALS INC 242
17.24.1 COMPANY SNAPSHOT 242
17.24.2 REVENUE ANALYSIS 242
17.24.3 PIPELINE PORTFOLIO 243
17.24.4 RECENT DEVELOPMENT 243
17.25 REJUVENATE BIOMED NV 244
17.25.1 COMPANY SNAPSHOT 244
17.25.2 PIPELINE PORTFOLIO 244
17.25.3 RECENT DEVELOPMENT 244
18 QUESTIONNAIRE 245
19 RELATED REPORTS 249